Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche to expand global biologic medicine manufacturing network

Roche to expand global biologic medicine manufacturing network

14th October 2013

Roche is to expand its global manufacturing network to increase production capabilities for biologic medicines over the next five years.

The company has announced that it will be spending 800 million Swiss francs (550.41 million pounds) on the work, which will be spread across its German and Swiss sites in Penzberg and Basel, as well as its US facilities in Vacaville and Oceanside.

Around 500 new jobs are expected to be created as a result of the expansion, which is being carried out in response to increased demand for licensed biologic medicines such as RoActemra, Kadcyla and Perjeta.

Roche also currently has 39 investigational biologic medicines in its pipeline, reflecting the fact that this is an important emerging field of research.

Daniel O'Day, chief operating officer of Roche's pharmaceuticals division, said: "Increasing our manufacturing capacity also highlights the confidence we have in the research and development of a range of new biologic medicines that will help serve unmet medical needs."

This comes after the firm nominated Christopher Franz, the outgoing chief executive of Lufthansa, as its new chairman last month.ADNFCR-8000103-ID-801648864-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.